

PANCREAS
DISEASE ORIENTED GROUP
AGENDA

CLOSED SESSION

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 29th, 2017

TIME: 15:00 - 15:45

CHAIRS: DR. ALICE WEI & DR. DANIEL RENOUF

-
- 15:00 WELCOME AND INTRODUCTION **DR. A. WEI / DR. D. RENOUF**
- 15:00 ACTIVE AND RECENTLY CLOSED TRIALS FOR UPDATE/DISCUSSION
- PA.6 (ACCORD 24):** RANDOMIZED MULTICENTER PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS A COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (MFOLFIRINOX) IN PATIENTS WITH RESECTED PANCREATIC ADENOCARCINOMA **DR. A. WEI / DR. J. BIAGI**
- PA.7:** A RANDOMIZED PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL VS. GEMCITABINE, NAB-PACLITAXEL, DURVALUMAB AND TREMELIMUMAB AS 1ST LINE THERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA **DR. D. RENOUF**
- 15:30 COMPASS/PANGEN SEQUENCING UPDATE **DR. D. RENOUF**
- 15:35 INTERGROUP TASK FORCE UPDATE **D. RENOUF / DR. A. WEI**
- 15:45 CLOSING REMARKS